Cash flow is fairly easy to estimate. Quarterly cash position from the CYDY SEC filing, 8k's for the raising of additional cash. The company's average monthly burn rate (from CYDY 10K annual report). So it is pretty simple to track their cash flow. They are getting drips and dribble in private investor financing through Paulson, but it covers only a few weeks of operating expenses.
The only thing that is keeping the lights on is the "private investors" that are buying deep discount shares they can sell quickly. When they dry up, no new cash.
Then there is the $100 million in mostly past due long-term debt. Samsung is owed $35 million that the company has paid none of. Samsung could sue and force bankruptcy. Then there is Fife's vulture fund that is owed a significant portion of the $60 million in convertible note. Fife could sue too.
Then there is Amarex debt that is in arbitration. CYDY could owe another $6 million.
So little bits of cash keeping the lights on until the long-term creditors decide to take legal action that likely will force CYDY into involuntary bankruptcy. They could do Chapter 11 protection and reorganize into who knows what with no new cash. Or Chapter 7 which is liquidation selling all the assets and Progenics/Abbvie takes back the LL patent rights.
Virtually all of these scenarios washout shareholders leaving them with nothing.